Palmira Alvarez

Triathlete

[Palmira Alvarez @Ironbarbie]

Happy week! Let’s go! 💪🏼

[Palmira Alvarez @Ironbarbie]

@HarifandiS62702 I guess helped I swam before doing my strength training

[Palmira Alvarez @Ironbarbie]

Thinking about racing next summer! 💪🏼

[Palmira Alvarez @Ironbarbie]

@slow_tri_guy Thanks! Actually it’s a personalized running outfit!

[Palmira Alvarez @Ironbarbie]

@steelhead2020 Olympic tris in Colorado!

[Palmira Alvarez @Ironbarbie]

@toffetaf I know right!? Probably the only one working out next to her smart phone 😌

[Palmira Alvarez @Ironbarbie]

Getting it! 💪🏼

[Palmira Alvarez @Ironbarbie]

@OmarBhoo 😂right

[Palmira Alvarez @Ironbarbie]

Swimming with my toddler!

[Palmira Alvarez @Ironbarbie]

@Donaldz09 He is 16 months!!! Thank you Donald! 🙏🏼

[Palmira Alvarez @Ironbarbie]

@DisgraceK Que tal están las roscas de mazapán? Las llegaste a probar ?!!

[Palmira Alvarez @Ironbarbie]

@Smith_CourtneyM Happy New Year beautiful

[Palmira Alvarez @Ironbarbie]

Happy New Year! 🎆 the best is yet to come always

[Palmira Alvarez @Ironbarbie]

1 hr 30 minutes today! Feeling good!

[Palmira Alvarez @Ironbarbie]

Starting the week just right! And finishing the year strong! 💪🏼

[Iñigo San Millán @doctorinigo]

New Lancet data on GLP-1 agonists 👇

A new paper in The Lancet eClinicalMedicine shows that when GLP-1 therapy is stopped, most people regain the lost weight and lose metabolic benefits. In practice, this means GLP-1s function as chronic, often lifelong therapy not a temporary fix.

To be clear, GLP-1 agonists are improving the health of many people, especially patients with obesity, type 2 diabetes and high cardiometabolic risk. For these individuals, weight loss can be genuinely life-changing.

The concern is not appropriate medical use but indiscriminate use. With millions already taking these drugs and numbers rising rapidly (specially with the new pill format), many users are not patients in the classical sense, but generally healthy or mildly overweight individuals. In this context, the risk–benefit balance changes. Once started, most users will need to stay on GLP-1s indefinitely or face significant rebound effects, often returning to baseline or worse.

As an important caveat: GLP-1s improve metabolic control, but they do not rebuild metabolic capacity. Without resistance training, meaningful metabolic work (Zone 2 and above), and adequate protein intake, long-term use may promote lean mass loss, low energy flux and increased frailty risk with aging.

In addition, we still lack long-term data on potential pancreatic, thyroid, and central neurotransmitter effects.

GLP-1s are powerful tools, but not a standalone solution. Long-term success requires pairing pharmacology with training and metabolic resilience.

IMHO: based on current clinical and research evidence, it is now urgent that clinicians clearly inform users that starting GLP-1 therapy likely means committing to long-term or lifelong use, with all the consequences that may entail.

https://t.co/uMTQKs13wH

[Palmira Alvarez @Ironbarbie]

Merry Christmas 🎄 hope you had a blessed day!

[Palmira Alvarez @Ironbarbie]

@BumpOwiggly Thank you! Gradually coming back!

[Palmira Alvarez @Ironbarbie]

Sunday ride ! 170 watts average, 1 hr 20 mins

[Palmira Alvarez @Ironbarbie]

Swim and strength to start the week just right! 🥳

[Palmira Alvarez @Ironbarbie]

@ClearPathU It’s a Cube (Tri bike)